3/22/2023 7:20:20 AM
Avadel Pharmas Announces FDA Approves Pre-Launch Activities Importation Requests For LUMRYZ
3/22/2023 7:16:44 AM
Tiziana Life Sciences Chairman And Acting CEO Gabriele Cerrone Purchases 8,000 Common Shares At $0.89/Shr
12/14/2022 6:02:49 AM
Tiziana Life Sciences Granted 180-day Extension By Nasdaq To Meet Minimum Bid Price Requirements
10/12/2022 7:20:31 AM
Tiziana Life Sciences Plans To Submit IND For Phase 1 Trial Of Intranasal Foralumab In Alzheimer's Disease Patients
9/23/2022 7:12:18 AM
Tiziana Life Sciences Announces Purchase Of 75K Shares At $0.83/Shr By Chief Medical Officer Matthew Davis
4/5/2022 7:16:43 AM
FDA Permitsto Enroll 8 Addl SPMS Patients In Expanded Access Program With Intranasal Foralumab
9/2/2021 2:25:01 AM
Precision BioSciences, Tiziana Life Sciences To Evaluate Foralumab With Allogeneic CAR T Candidates For Cancer Treatment
8/20/2021 3:53:32 AM
Tiziana Life Sciences To Delist From LSE
6/23/2021 3:42:27 AM
Tiziana Agrees With FHI Clinical To Conduct Phase 2 Clinical Trial For COVID-19 Patients With Intranasal Foralumab
6/21/2021 2:36:16 AM
Tiziana Appoints Kevin Schutz As VP Of Regulatory Affairs
1/13/2021 2:34:13 AM
Tiziana Life Sciences Appoints Neil Graham Chief Medical Officer